Physician profile
Jon O Sides
NPI 1912901885
$4,642.03
in general payments reported to CMS, 2019-2025
42 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $286 · 2021: $474 · 2022: $1,413 · 2023: $587 · 2024: $520 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.87 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $679.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $358.73 | 2022-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $302.35 | 2021-2024 | Mounjaro |
| Amgen INC. | $209.06 | 2019-2025 | Evenity, Prolia, Prolia |
| Sunovion Pharmaceuticals INC. | $199.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $159.81 | 2020-2022 | |
| Pfizer INC. | $140.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.78 | 2019-2022 | |
| Abbott Laboratories | $117.56 | 2022-2023 | Freestyle Libre 2 |
| Allergan, INC. | $103.08 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $93.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $91.77 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $82.95 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Sides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.